Investigational drug · Phase 2
TG4050
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Squamous Cell Carcinoma of Head and Neck.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TG4050"
First trial start
2019
Dec 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TG4050", any sponsor or status.
Conditions studied
As listed on its trial records.
- Squamous Cell Carcinoma of Head and Neck
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TG4050" as an intervention, largest first.
- A Clinical Trial Evaluating TG4050 in Head and Neck CancerActive, not recruiting
TransgeneIndustry
NCT04183166 · 80 participants · Start Dec 12, 2019 · Primary completion Dec 30, 2027
Drug: TG4050 · For: Squamous Cell Carcinoma of Head and Neck
Sites: Jacksonville, Florida; Bordeaux, France; Marseille, France · 14 sites in all
TransgeneIndustry
NCT03839524 · 64 participants · Start Dec 9, 2019 · Primary completion Oct 8, 2024
Drug: TG4050 · For: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Carcinoma
Sites: Phoenix, Arizona; Jacksonville, Florida; Rochester, Minnesota · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.
Ottensmeier C, Delord JP, Lalanne A, et al. · Nat Commun 2026
- Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation.
Filippini DM, Le Tourneau C · Transl Oncol 2026
Also in development for Squamous Cell Carcinoma of Head and Neck
- SI-B001Phase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- ImzokitugBMS-986340Phase 22 trials
Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer
- DM005Phase 21 trial
Doma Biopharmaceutical(Suzhou)Co., Ltd. · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
- EvalstotugBA3071Phase 21 trial
BioAtla, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck
- TH9619Phase 21 trial
One-carbon Therapeutics AB · Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.